Analyzing selected FDA approved drugs for effects on template switch mutagenesis in E. coli
Year: 2025
Type: article
Abstract: Quasipalindromes (QPs) are DNA sequences that are imperfectly mirrored, known to form secondary structures like hairpins and cruciforms. These sites have been linked with a specific type of mutation called template-switch mutation (TSM). Certain drugs like 5-azaC, AZT, and ciprofloxacin are known to induce TSM. This study aims to assess the impact of five FDA-approved drugs—three antitumor drugs (CPT-11, Doxorubicin hydrochloride, and Gemcitabine hydrochloride) and two anti-inflammatories (Ibuprofen and Dexamethasone)—on template-switch mutagenesis. The findings reveal no statistically significant effects on frequency of mutations after treatment with Gemcitabine hydrochloride, Ibuprofen, Dexamethasone, or Doxorubicin hydrochloride. However, CPT-11 treatment showed a notable decrease in TSM, suggesting a potential role in disrupting the template-switching process.
Source: Fine Focus
DOI: 10.33043/rq7a84ax
Authors: April Swain, Emily Colburn, Kamila De Andrade, Pamela Rosales, Sydney Addorisio, Taylor Stuart, Angelina Galvao, Leigha Hubisz, Margaret Ouellette, Rana Hamssa, Laura Laranjo, Cara Pina
Institutions: Framingham State University, Salem State University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4412478551